Pyrazolam

Pre-existing compromised respiratory function including COPD, obstructive sleep apnea, and neuromuscular respiratory weakness increases vulnerability to GABA-A-mediated respiratory depression. Pyrazolam's allosteric enhancement of GABAergic inhibition in brainstem respiratory centers can suppress compensatory ventilatory drive.

Benzodiazepine-mediated muscle relaxation combined with respiratory depression can precipitate myasthenic crisis in patients with myasthenia gravis. Pyrazolam produces dose-dependent muscle relaxation via GABA-A receptor enhancement.

Prior benzodiazepine use disorder significantly increases risk of re-initiation of dependence. Full cross-tolerance exists between pyrazolam and all benzodiazepines, meaning prior dependence on any GABAergic agent increases risk of rapid tolerance development and compulsive use.

Although pyrazolam's metabolic fate is unresolved (three-way contradiction in published literature regarding hepatic metabolism), any hepatic processing could be impaired in liver disease, prolonging exposure duration. Class-level precaution applies to all benzodiazepines.

Benzodiazepines carry teratogenic risk particularly with first-trimester exposure and neonatal withdrawal risk with late-pregnancy exposure. No pyrazolam-specific reproductive or developmental toxicity data exist. Class-level absolute contraindication.

opioids, alcohol, barbiturates, GHB/GBL, other benzodiazepines, gabapentinoids

Active use of opioids, barbiturates, alcohol, GHB, or other benzodiazepines constitutes an absolute contraindication due to synergistic respiratory depression risk. The Lehmann 2019 fatality and Magny 2026 poisoning both involved polydrug contexts. Co-administration eliminates the pharmacological ceiling that protects against benzodiazepine monointoxication fatality.

Some benzodiazepines can increase intraocular pressure. Class-level precaution applies, though this is a lower-priority contraindication with limited direct evidence for pyrazolam.